Article citationsMore>>

Meyerholz, D.K., Stoltz, D.A., Namati, E., Ramachandran, S., Pezzulo, A.A., Smith, A.R., Rector, M.V., Suter, M.J., Kao, S., McLennan, G., Tearney, G.J., Zabner, J., McCray Jr., P.B. and Welsh, M.J. (2010) Loss of cystic fibrosis transmembrane conductance regulator function produces abnormalities in tracheal development in neonatal pigs and young children. American Journal of Respiratory and Critical Care Medicine, 182, 1251-1261. doi:10.1164/rccm.201004-0643OC

has been cited by the following article:

• TITLE: Cell based therapy aides in infection and inflammation resolution in the murine model of cystic fibrosis lung disease

  AUTHORS: Tracey L. Bonfield, Donald Lennon, Santosh K. Ghosh, Amy M. DiMarino, Aaron Weinberg, Arnold I. Caplan

  KEYWORDS: Inflammation; Mesenchymal Stem Cells; Antimicrobial Activity

  JOURNAL NAME: Stem Cell Discovery, Vol.3 No.2, April 25, 2013

  ABSTRACT: Cystic fibrosis (CF) is a genetically inherited disease which is characterized by excessive inflammation and inability to resolve infection with pathogens such as Pseudomonas aeruginosa. Treatment options have improved with correctors and potentiators, but a cure remains elusive. Human mesenchymal stem cells (hMSCs) have the potential to be both anti-inflammatory and anti-microbial, which makes them ideal candidates for exploration as an innovative new therapeutic for CF. Using a sublethal CF mouse model of chronic Pseudomonas aeruginosa infection, we show that hMSCs and wild type bone marrow derived macrophages (BMM) have the capacity to attenuate inflammation while at the same time improving the ability to resolve infection. Animals infected with bacteria and treated with hMSCs and BMM had less weight lost, decreased pro-inflammatory cytokines, decreased severity of gross lung pathology as well as clinical score. Importantly, even though the inflammation was decreased in vivo, both BMM and hMSC treatment resulted in significant decrease in lung bacterial load. The improvement in the CF model was consistent with hMSC induced anti-inflammatory and anti-microbial activity which may involve the cathelicidin LL-37. These studies suggest that both healthy MSCs and BMM may provide important new direction toward cell based therapies in CF.